FOLH1 and prostate cancer: The tumour sink effect, which is characterized by lower tracer accumulation in the normal organs of patients with high tumour burden, has been demonstrated with therapies targeting PSMA and SSTR in prostate cancer and well-differentiated neuroendocrine tumours, respectively [26].